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The long term outcome of limbal allografts: the
search for surviving cells
Timothy R M Henderson, Douglas J Coster, Keryn A Williams
Abstract
Background/aims—Limbal allotransplan-
tation is increasingly being used for ocular
surface repair in patients with limbal stem
cell dysfunction. However, it is uncertain
whether donor cells survive long term on
the ocular surface and whether patients
maintain the early benefits of the proce-
dure. The aims of this study were to inves-
tigate the long term outcome of clinical
limbal allografts and to correlate outcome
with donor cell survival.
Methods—Five patients who had under-
gone allotransplantation—four keratolim-
bal allografts and one tarsoconjunctival
allograft—from 3–5 years previously, and
for whom residual frozen donor ocular tis-
sue was available, were reviewed. Survival
of donor cells lifted from the recipient
ocular surface by impression cytology was
investigated by DNA fingerprinting using
primers detecting variable nucleotide tan-
dem repeat sequences. Recipient buccal
cells and scleral samples from the remnant
donor eye were used to genotype recipients
and donors, respectively. Polymerase chain
reaction products were sized by Genescan
analysis.
Results—An objective long term benefit
from the procedure (improved Snellen
acuity, reduced frequency of epithelial
defects, reduced vascularisation, and
scarring) was recorded for four patients.
Some subjective benefit was also reported.
However, in no instances were donor cells
recovered from the ocular surface at 3–5
years post-graft. Initial experiments to
examine sensitivity indicated that any
surviving donor cells must have consti-
tuted less than 2.5% of cells sampled.
Conclusion—Limbal stem cell allotrans-
plantation can provide long term benefits,
as measured by objective criteria. How-
ever, such benefits do not necessarily
correlate with survival ofmeasurable num-
bers of donor cells on the ocular surface.
(Br J Ophthalmol 2001;85:604–609)
Ever since the pioneering work of Thoft and
his colleagues1–3 and, more latterly, Tseng and
his colleagues4–7 demonstrated the value of
conjunctival and limbal transplantation for
limbal stem cell dysfunction, clinical limbal
allotransplantation has been embarked upon
with some enthusiasm.7–12 The use of corneal
stem cell autografts is now well established in
cases of unilateral stem cell deficiency.13 14
Support for the eYcacy of corneal stem cell
allotransplantation remains more tenuous, but
the procedure has been reported to result in
stabilisation of the ocular surface in cases of
bilateral disease, with reduction in symptoms at
least in the short term, and early visual rehabili-
tation.10 11 However, some recent studies have
shown evidence for relatively limited survival of
donor cells on the ocular surface.15 16 The issue
of whether adequate immunosuppression
might significantly improve graft survival re-
mains unresolved but has some support in both
clinical11 17 and experimental studies.18–20 The
purpose of this study was to investigate the long
term outcome of limbal stem cell transplanta-
tion and to correlate graft outcome with donor
cell survival on the ocular surface.
Materials and methods
PATIENTS
A heterogeneous group of five patients who
had undergone limbal or tarsoconjunctival
allotransplantation between 3 and 5 years pre-
viously and for whom residual donor eye tissue
had been frozen at −20°C was identified. The
details of patient presentation, indications for
surgery, operative procedure performed, dura-
tion of follow up and the immunosuppression
administered postoperatively are shown in
Table 1. Patient D formed the subject of an
earlier report in which follow up extended for
20 weeks postoperatively.15 Patients were re-
viewed in the clinic by an ophthalmologist not
otherwise connected with the care of these
individuals and all grafted eyes were photo-
graphed. Each patient was questioned as to
whether he or she had experienced subjective
benefit from the procedure. This study was
undertaken with institutional approval and the
informed consent of all patients involved.
EXTRACTION OF GENOMIC DNA FROM BUCCAL
CELLS, SCLERA, CORNEAL EPITHELIAL CELLS, AND
PERIPHERAL BLOOD LYMPHOCYTES
Buccal cells and scleral samples from the rem-
nant donor eye were used to genotype
recipients and donors, respectively. Buccal cells
were obtained by a brief mouthwash with ster-
ile water. Cells from 1 ml of mouthwash
sample were pelleted 1 minute at 4000 g.
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Genomic DNA was extracted by incubating
the cells at 60°C for 2 hours in 25 µl of extrac-
tion buVer containing 60 µg/ml proteinase K,
followed by 15 minutes of incubation at
95°C.15 Frozen remnant donor eyes were
partially thawed to allow a 3 × 5 mm fragment
of sclera to be dissected. In the case of patient
C who had undergone two graft procedures
from two diVerent donors, remnants of both
donor eyes were available. Scleral fragments
were pulverised in a sterile metal mortar and
pestle, precooled with liquid nitrogen. The
resulting powder was transferred to sterile
eppendorf tubes and genomic DNA extracted
in 200 µl of FTA buVer (Fitzco Inc, Maple
Plain, MN, USA) according to the manufac-
turer’s recommendations. Corneal epithelial
cells from the ocular surface of patients with
limbal allografts were harvested by impression
cytology using 6 mm discs of FTA paper and
processed according to the manufacturer’s rec-
ommendations. Impression cytology was per-
formed on both the central and peripheral cor-
nea of each grafted eye. Venous peripheral
blood was collected from two healthy volun-
teers into heparinised tubes. Peripheral blood
lymphocytes (PBL) were purified over Ficoll-
Hypaque gradients, washed in sterile 0.9%
saline, and resuspended to 1.5 × 106 cells/ml.
DNA was extracted in the same manner as for
buccal cells.
DNA FINGERPRINT ANALYSIS
All analyses were performed on at least two
occasions. FTA paper discs were cut with a
sterile blade into 1 × 2 mm fragments and a
single fragment used in each reaction. Four
forensic forward and reverse primers labelled
with fluorescent dyes were provided by Dr F
Firgaira (Department of Haematology,
Flinders Medical Centre, Adelaide, Australia).
D165393-hex and D165498-fam detected
dinucleotide repeats of allele size 130–158 base
pairs (bp) and 208–246 bp, respectively.
D165539-fam and vWF-1-fam detected
tetranucleotide repeat sequences of allele size
148–172 bp and 150–180 bp, respectively.
Optimised polymerase chain reaction (PCR)
mixtures were: 1.2 µl 25 mM MgCl2, 1.0 µl 4
mM dNTPs, 2.0 µl 10x buVer, 0.2 µl 1.0 U
Taq-gold polymerase (all from Perkin Elmer
Roche Molecular Systems, Branchburg, NJ,
USA), 1.0 µl 100 ng/µl forward primer, 1.0 µl
100 ng/µl reverse primer, 8.6 µl water.
Thermocycler conditions were: one cycle at
95°C for 10 minutes; 10 cycles at 94°C for 30
seconds, 60°C for 30 seconds, and 72°C for 1
minute; 35 cycles at 94°C for 30 seconds; 55°C
for 30 seconds and 72°C for 1 minute, final
cycle at 72°C for 10 minutes and 35°C for 10
seconds. PCR products were visualised on
ethidium bromide agarose gels before being
sized on an automated DNA sequencer that
used Genescan software (Applied Biosystems
Inc, La Jolla, CA, USA).
SENSITIVITY OF DETECTION OF PCR
The sensitivity of detection of the PCR was
established in preliminary experiments using
known concentrations of PBL. Firstly, 10-fold
dilutions of PBL from a single donor in Dulbec-
co’s A phosphate buVered saline (PBS) were
prepared and the DNA extracted. Secondly, two
reciprocal dilution series in which cells from one
PBL donor were diluted with cells from the
other donor were set up and similarly extracted.
Initial experiments showed that 30–40 cells in a
sample of PBL from a single donor could
reliably be fingerprinted, whereas no adequate
Genescan product peaks could be detected in
samples containing three to four cells (data not
shown). Dilution series using PBL from two dif-
ferent individuals indicated that it was possible
to identify the minority cell type in a mixed cell
sample when it constituted 2.5% or more of the
sample (data not shown).
Table 1 Details of patients, presenting diseases, procedure performed, duration of follow up, and immunosuppression
Patient age at
graft (years), sex Indication for limbal allograft Procedure
Duration follow
up (months) Immunosuppression, duration treatment
(A) 50, M Epithelial dysplasia aVecting both eyes and skin R 360° limbal allograft 36 prednisolone phosphate 0.5% qds, 4 months
(B) 34, F Aniridic keratopathy, worse in right eye
(primary limbal failure)
R 360° limbal allograft 45 prednisolone phosphate 0.5% qds, 13 months
(C) 71, M Limbal carcinoma in situ, biopsy proved
recurrence, previous limbal graft failure
R 360° limbal allograft; corneal
surface replaced
54 prednisolone phosphate 0.5% qds, 4 months
prednisolone phosphate 0.5% bd, 50 months
(D) 47, F Contact lens induced limbal failure R limbal allograft 2 × 3 clock hours 56 prednisolone phosphate 0.5% qds, 28 months
cyclosporin 200–100 mg bd, 56 months
azathioprine 100–25 mg od, 15 months
(E) 67, M Subtarsal well diVerentiated squamous cell
carcinoma with invasive foci
L upper lid tarsoconjunctival
allograft; corneal surface replaced
56 prednisolone phosphate 0.5% qds, 1 week
prednisolone phosphate 0.5% tds, 11 months
mitomycin C 0.02% od, alternate weeks
qds = four times daily; bd = twice daily; od = once daily; tds = three times daily.
Table 2 Clinical outcomes after limbal or tarsoconjunctival allotransplantation
Patient
Preoperative acuity
(with PH)
Best postoperative
acuity (with PH)
Long term
acuity
Subjective
benefit Objective benefit
A HM HM HM Yes Reduced frequency of epithelial defects
B CF CF CF Yes None
C 6/36 6/18 6/24 Yes Reduced vascularisation, stromal scarring, and
epithelial defects. No recurrence of limbal carcinoma
in situ but corneal surface is keratinised
D 6/60 (6/9) 6/12 (6/9) 6/18 Yes Reduced degree of stromal scarring
E 6/36 (6/18) 6/18 CF No No recurrence of carcinoma; ocular surface is
completely keratinised
PH = pinhole, HM = hand movements, CF = counting fingers at 1 metre.
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Results
CLINICAL OUTCOME OF LIMBAL
ALLOTRANSPLANTATION
The clinical outcome for each patient at 3–5
years after limbal allotransplantation is sum-
marised in Table 2. A long term improvement
in Snellen acuity without pinhole was recorded
for two patients and other objective benefit was
apparent for four patients. All patients reported
that they would undergo the same procedure
again, even with the benefit of hindsight. With
the exception of patient E who had received a
tarsoconjunctival allograft for carcinoma in
situ, all patients considered that the procedure
Figure 1 Clinical
photographs of operated
eyes showing the
appearance immediately
preceding surgery on the left
hand side and the
appearance of the same eye
at the study review on the
right hand side.
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had helped them. Ocular surface comfort
improved for patients A, C, and D. Functional
capability improved with benefit to peripheral
vision (patient C), ability to drive a car (patient
D), and ease of reading (patient B). Figure 1
shows the preoperative appearance of the
grafted eye for each patient, together with the
appearance at the most recent follow up.
DNA FINGERPRINTING OF RECIPIENTS, DONORS,
AND GRAFTED EYES
DNA fingerprints were obtained from all sam-
ples tested, and no diVerence was found in
samples obtained from the central or periph-
eral cornea of any patient. A representative
Genescan trace obtained for patient C is shown
in Figure 2. The DNA fingerprint analyses for
each recipient, donor, and for cells harvested
from eyes bearing limbal allografts are shown
in Table 3. With the exception of a single buc-
cal cell sample from patient E, primers detect-
ing alleles at each of the microsatellite loci gave
clear peaks within the correct product size
range, and individuals were clearly hetero-
zygous or homozygous at each locus. For
patient E, an anomalous peak not correspond-
ing to either the donor or the recipient buccal
sample was obtained in DNA harvested from
the tarsal surface, but overall, suYcient prod-
uct peaks were present to show that the tarsal
conjunctival sample matched the buccal cell
sample. One allele detected at one locus in
patient A matched that of the donor and the
finding was consistent upon repeat scanning.
However, the absence of any other discrimina-
tory peaks from the donor suggested that
significant donor cell survival had not oc-
curred. In summary, no unequivocal evidence
for survival of donor derived cells on the ocular
surface of the grafted eyes was obtained for any
of the five patients.
Discussion
The transplantation of populations of ocular
epithelial stem cells from donor eyes has
become an established surgical treatment for
severe ocular surface disease secondary to stem
cell dysfunction. The short term benefits of
such procedures to the recipient are often
plain. However, long term benefits remain
somewhat uncertain, possibly because grafts of
histoincompatible tissue do not survive after
transplantation. Certainly, immunosuppres-
sion is usually administered to recipients of
limbal allografts with the explicit goal of
preventing allograft rejection. We examined
five patients at 3–5 years after limbal allotrans-
plantation in order to correlate long term
outcomes with survival of donor cells on the
ocular surface. This study diVers from those
we have reported previously10 15 16 in several key
aspects. Firstly, multiple microsatellite markers
were used to improve the chances of detecting
surviving donor cells on the ocular surface.
Secondly, the patients in this study had been
followed for at least 3 years after surgery, by
which time we could be reasonably certain that
outcomes were relatively stable. We were thus
in a position to determine long term benefits, if
any, to the recipients.
In spite of the disparate indications for allo-
grafting in our patients, the long term outcome
for the group as a whole was one of qualified
improvement, with some stabilisation of the
ocular surface after 3–5 years of follow up.
Interestingly, the subjective benefit was dispro-
portionately greater than the objective findings
would have suggested, particularly given that
we were unable to show significant levels of
surviving donor cells on the ocular surface of
the grafted eye in any of the patients investi-
gated.
Microsatellite markers21 were used to iden-
tify the genotype of cells lifted from the ocular
surface by impression cytology. Of the four
variable nucleotide tandem repeat loci exam-
ined, two were dinucleotide repeats and two
were tetranucleotide repeats. The Genescan
product peaks obtained with the latter were
better defined with fewer stutter bands than
were the former. A degree of preferential
amplification of product occurred during PCR
with the dinucleotide repeat primers but was
insuYcient to aVect resolution. Any Genescan
product peak diVering by more than two base
pairs may be utilised as a clearly discriminatory
peak, and the greater the number of markers
used, the smaller the chance that any two indi-
viduals will be identical at all loci examined. In
the five patients examined in this study, all four
markers were discriminatory between donor
and recipient in three instances, and three of
four were discriminatory in the remaining two
instances.
The nature of PCR is such that amplification
of a more prevalent sequence is favoured at the
expense of a minority sequence. In a mixed cell
population such as is at least theoretically rep-
resented by the grafted ocular surface, the limit
of detection of the minority species might be
higher than otherwise expected. Preliminary
experiments suggested that a minority cell
population would be detectable only if it
constituted 2.5% or more of the sample. It fol-
lows that should any donor cells be surviving
Table 3 DNA fingerprint analyses—all numbers refer to Genescan peak positions in base
pairs
Patient Sample D165393
Microsatellite primer: Evidence for
donor cell
survival?D165498 D165539 vWF-1
(A) Recipient 145 155 219 245 151 159 164 168
Donor 141 154 209 − 151 163 158 164
Ocular
surface
141 154 219 245 150 158 164 168 No
(B) Recipient 141 151 218 245 163 167 168 176
Donor 135 148 219 223 151 167 168 176
Ocular
surface
142 152 219 245 163 167 168 176 No
(C) Recipient 142 148 − 245 155 175 168 176
Donor 1 141 153 220 245 158 162 164 −
Donor 2 143 156 218 − 159 167 164 168
Ocular
surface
142 148 − 245 154 174 168 176 No
(D) Recipient 141 − 218 223 151 159 164 168
Donor 135 148 219 223 151 167 168 176
Ocular
surface
141 − 219 223 150 158 164 168 No
(E) Recipient 146 150 219 − − 166 − 168
Donor 141 155 209 219 151 163 164 168
Tarsal surface 146 150 219 245 156 167 160 168 No
Figures in bold type indicate discriminatory alleles which, had they been found in the ocular sur-
face sample, would have indicated persistence of donor cells.
− = absence of a second allele, usually resulting from homozygosity at that locus but rarely result-
ing from preferential amplification or failure of amplification during PCR.
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on the ocular surface of our patients, those cells
must constitute less than 2.5% of the popula-
tion of cells sampled by impression cytology.
Sampling achieved by impression cytology may
be patchy, but generally the superficial two to
three layers of the epithelial surface are lifted
oV with the impression.22 It is possible that
some donor derived stem cells or transient
amplifying daughter cells might persist in the
basal epithelium and thus not be sampled.
However, it should be noted that two of the
patients described in this study underwent
procedures in which essentially the entire ocu-
lar surface was replaced with donor tissue.
If very low levels of donor stem cells persist
long term or if such cells do not persist at all, it
is interesting to speculate how limbal allotrans-
plantation might stabilise the ocular surface.
Possibly the graft matrix improves the local
environment for residual host stem cells, which
are then enabled to repopulate the ocular
surface suYciently to allow the patient to per-
ceive an improvement. Perhaps grafted cells
enhance the stem cell “niche” by provision of
growth factors or soluble mediators. The
actual surgical procedure and subsequent
healing response may help to reduce neovascu-
larisation and scarring at least in the short
term, especially if superficial keratectomy has
been performed. It is not yet known to what
extent immunosuppression can prevent or
delay the decline in numbers of donor cells that
plainly occurs with time. It is, however, clear
that donor stem cells do not necessarily
stabilise the ocular surface by substantial
repopulation of the epithelium as originally
envisaged. The one recipient in our series
(patient D) who remained on oral cyclosporin
for almost 5 years showed no evidence of donor
cell survival on the ocular surface. However, it
proved diYcult to wean her oV systemic
cyclosporin despite side eVects including hir-
sutism and voice changes. Ocular discomfort
and significant conjunctival and limbal hyper-
aemia recurred whenever attempts were made
to taper the cyclosporin dosage. It seems likely
that an underlying dysplasia may have been
kept in remission by the immunosuppression.
In conclusion, this study suggests that the
assumption that stabilisation of the ocular sur-
face after limbal allotransplantation is corre-
lated with significant levels of donor cell
survival may not be merited. Stabilisation does
occur, although early improvement may re-
gress after some months. Some objective and
subjective benefits to the recipient may be
apparent in the absence of detectable levels of
donor cell survival on the ocular surface.
Persisting subjective improvement may repre-
sent a placebo eVect, at least in part, but may
also reflect a hitherto unrecognised biological
eVect of the transplantation procedure. The
value to the patient should not be underesti-
mated, but the risks associated with prolonged,
systemic immunosuppression may not be justi-
fied.
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